Shenlu Biotech

Beijing Shenlu Biopharmaceutical is a prominent Chinese biotechnology company dedicated to the development of neurotrophic factor-based therapeutics. The company's core product, Enjingfu (Mouse Nerve Growth Factor for Injection), is a leading treatment in China for peripheral nerve injuries and nerve regeneration. Shenlu Biotech leverages its expertise in recombinant protein technology to maintain a specialized pipeline focusing on neurological and ophthalmic disorders. Key research areas include neurotrophic keratitis and optic nerve damage, where the company is conducting advanced clinical trials. With integrated R&D and GMP-certified manufacturing facilities in Beijing, Shenlu is positioned as a key player in the neuro-biotech sector in East Asia. The company was listed on China's National Equities Exchange and Quotations in 2015.